Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31522187 | 0.98 | F10 (0.48) | F10KDM4EMEN1ALDH1A1GLA | |
| SCHEMBL30620409 | 0.88 | PRMT5 (0.46) | F10KDM4EMEN1ALDH1A1GLA | |
| SCHEMBL10279507 | 0.86 | F10 (0.50) | F10KDM4EHPGDF2GRM5 | |
| SCHEMBL1251008 | 0.86 | F10 (0.50) | F10KDM4EALDH1A1MAPTF2 | |
| Lithium SCHEMBL30832626 | 0.84 | F10 (0.49) | F10KDM4EALDH1A1MAPTF2 | |
| SCHEMBL207703 | 0.84 | F10 (0.49) | F10KDM4EALDH1A1MAPTF2 | |
| Hydrochloric Acid SCHEMBL209036 | 0.84 | F10 (0.49) | F10KDM4EALDH1A1MAPTF2 | |
| SCHEMBL20328964 | 0.84 | F10 (0.52) | F10F2GRM5 | |
| SCHEMBL19288520 | 0.84 | F10 (0.49) | F10F2GRM5ALOX15 | |
| Hydrochloric Acid SCHEMBL20293520 | 0.83 | F10 (0.51) | F10F2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-111936475-A | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2020-11-13 | — | — | CN | claimed |
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | CHULALONG UNIVERSITY (TH) | 2024-10-10 | — | — | US | disclosed |
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023223346-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF EDOXABAN INTERMEDIATE | MYLAN LABORATORIES LIMITED (IN) | 2023-11-23 | — | — | WO | disclosed |
| CN-114650993-A | PD-1/PD-L1 inhibitor and preparation method and application thereof | 上海华汇拓医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-111606826-B | Preparation method of edoxaban intermediate | 沧州那瑞化学科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-111936475-A | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019158550-A1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | MOEHS IBERICA, S.L. (ES) | 2019-08-22 | — | — | WO | disclosed |
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | APOTEX INC. (CA) | 2019-05-28 | — | — | US | disclosed |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-2980067-B1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1270557-B1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2374456-A1 | ACTIVATED BLOOD COAGULATION FACTOR X (FXA) INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | PDCD1, PDCD1LG2, CD274 | F10 4383/4885KDM4E 621/4885MEN1 3191/4885 |
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | VKORC1, CYP2C9, VKORC1L1 | F10 26/4885KDM4E 488/4885MEN1 1974/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | F10 26/4885KDM4E 488/4885MEN1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.